Research · head to head
Genedata vs Seven Bridges
Genedata
Research
Enterprise R&D data platforms for biologics, screening and bioprocess, owned by Danaher
- From
- On request
- Rated
- -
Seven Bridges
Research
Cloud bioinformatics platform and trusted research environment, sold by Velsera
- From
- On request
- Rated
- -
The short version
- Each has a real cost: Genedata there is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.; Seven Bridges the parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
- They diverge on capability: Genedata covers Screener, Seven Bridges covers Trusted research environment.
- Prices and features above were last checked on 31 August 2026.
Where they differ
Only the attributes on which Genedata and Seven Bridges actually diverge.
| Attribute | Genedata | Seven Bridges |
|---|---|---|
| Platforms | Web, On-premise, Private cloud | Web, API, Cloud |
Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).
What each one covers
Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.
Only in Genedata
- Screener
- Biologics
- Bioprocess
- Expressionist
- Selector
- Profiler
- Instrument integration
- GxP-capable deployments
Only in Seven Bridges
- Trusted research environment
- Cloud-agnostic
- CWL pipelines
- Compliance certifications
- Cost prediction
- Public data commons
- Collaboration
- Tool library
What people use each for
The jobs each tool is most often brought in to do.
Genedata
- A pharmaceutical screening group processing thousands of plates a week where manual QC and curve fitting no longer scalenot Seven Bridges
- A biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheetsnot Seven Bridges
- A process development group standardising bioprocess run data across sites for modelling and scale-upnot Seven Bridges
- A CRO delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelinesnot Seven Bridges
Seven Bridges
- A cancer genomics group analysing controlled-access dbGaP data that cannot be moved to local infrastructurenot Genedata
- A federal or federally funded programme that needs FedRAMP Moderate authorisation for its analysis environmentnot Genedata
- A multi-institution consortium sharing pipelines and results under defined access controls rather than by emailing filesnot Genedata
- A diagnostics developer building reproducible CWL pipelines that must stand up to later regulatory reviewnot Genedata
Where each one falls short
Documented limitations, not opinions. Every one is a constraint you would hit in normal use.
Genedata
- There is no entry level and no published price at any tier, so a mid-sized biotech cannot even establish whether Genedata is in its range without a lengthy sales engagement.
- Platforms are licensed individually and most organisations need two or three, so the real contract is a sum of separate licences plus the integration work between them.
- Deployment is a services programme rather than an installation, running months and requiring scientific configuration by the vendor, which means value arrives long after the first invoice.
- Danaher ownership since 2023 gives the roadmap a natural pull toward Danaher instrument and bioprocessing lines, which is an advantage on that hardware and a question to ask if your instrument estate is from competitors.
- Validated deployments for regulated use add scope, cost and an ongoing revalidation obligation on your side after each vendor release, and that recurring internal effort is rarely counted in the business case.
Seven Bridges
- The parent merged into Velsera in 2023 alongside Pierian and UgenTec, so the platform now competes for roadmap attention with clinical interpretation and diagnostics products inside a private equity owned group.
- Pricing is not published and splits into a platform subscription plus consumption-based cloud compute, so a heavy analysis quarter produces a bill that headcount-based budgeting does not anticipate.
- The analysis capability itself has credible open source equivalents in Nextflow and Cromwell on raw cloud, so you are principally paying for compliance and governance rather than for the science.
- Pipelines are built around Common Workflow Language, which is a real learning curve and a portability commitment for teams whose existing work is in other workflow languages.
- Cloud storage of large genomic datasets accrues continuously whether or not you are analysing, and egress charges apply when moving results out, both of which are outside the subscription line.
Pricing, plan by plan
Genedata
On request- Genedata platform licence$undefined/year
- Each platform, such as Screener or Biologics, licensed separately
- Annual enterprise subscription scoped on users, sites and data volume
- Implementation and scientific configuration services quoted as a separate programme
Seven Bridges
On request- Seven Bridges Platform$undefined/year
- Platform subscription quoted through Velsera sales
- Cloud compute and storage charged on consumption on top of the subscription
- Cost predictor tools provided to estimate analysis spend in advance
Which should you pick?
Choose Genedata if
- You need screener.
- You work on Web, On-premise, Private cloud.
- You also want biologics.
Choose Seven Bridges if
- You need trusted research environment.
- You work on Web, API, Cloud.
- You also want cloud-agnostic.
Questions people ask
- Is Genedata or Seven Bridges better?
- Neither clearly leads. Genedata starts at On request and Seven Bridges at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
- Which is cheaper, Genedata or Seven Bridges?
- Genedata starts at On request and Seven Bridges at On request.
- Does Genedata or Seven Bridges run on more platforms?
- Genedata runs on Web, On-premise, Private cloud. Seven Bridges runs on Web, API, Cloud.
- What is Genedata best used for?
- Genedata is most often used for a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale, a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets, a process development group standardising bioprocess run data across sites for modelling and scale-up, a cro delivering high-throughput screening results to sponsors that require documented, reproducible analysis pipelines. Of those, a pharmaceutical screening group processing thousands of plates a week where manual qc and curve fitting no longer scale and a biologics discovery team linking antibody sequence, expression and assay data across a campaign instead of in spreadsheets are not what Seven Bridges is typically brought in for.
- What can Genedata do that Seven Bridges cannot?
- Genedata covers Screener, Biologics, Bioprocess, Expressionist. Seven Bridges covers Trusted research environment, Cloud-agnostic, CWL pipelines, Compliance certifications.
Answered from the vendors’ own pages
Genedata: Who owns Genedata?
Danaher acquired the company in 2023. It remains headquartered in Basel and continues under the Genedata name.
Seven Bridges: Is Seven Bridges still sold?
Yes. It is sold by Velsera, formed in 2023 when Summa Equity merged Seven Bridges with Pierian and UgenTec. The Seven Bridges name was retained for the platform.
Genedata: Is there a small-team or starter option?
No. Everything is an enterprise contract scoped by users, sites and data volume, with services attached.
Seven Bridges: What compliance does it hold?
FedRAMP Moderate, SOC 2, HIPAA, GDPR, dbGaP and ISO 27001, 27017, 27018 and 27701, which is the usual reason institutions choose it over building on raw cloud.
Genedata: Do I buy one product or the whole suite?
Each platform is licensed separately. Most customers license two or three and integrate between them.
Seven Bridges: How is it priced?
Not published. Expect a platform subscription plus consumption charges for cloud compute and storage.
Genedata: Can it be used in a GxP environment?
Yes, with a validated deployment contracted as additional scope. Ongoing revalidation after releases remains your responsibility.
Seven Bridges: Do I have to use a specific cloud?
No. The platform is cloud-agnostic and designed to bring analysis to where the data already resides.
Related pages
More on Seven Bridges
Other head to heads
- Genedata vs LabVantage
- Genedata vs Benchling
- Genedata vs Sapio Sciences
- Genedata vs Medidata Rave
- Genedata vs Castor EDC
- Genedata vs Suzy
- Genedata vs Terra
- Genedata vs LabWare
- Genedata vs Aurelius
- Genedata vs Chemaxon
- Genedata vs Labguru
- Genedata vs Schrodinger
- Genedata vs TetraScience
- Genedata vs Thermo SampleManager LIMS
- Genedata vs Valispace
- Genedata vs Wolfram Mathematica
- Genedata vs DNAnexus
- Genedata vs Dotmatics
- Genedata vs Form Bio
- Genedata vs Greenphire
- Genedata vs OpenEye, Cadence Molecular Sciences
- Genedata vs Attest
- Genedata vs NVivo
- Genedata vs Scispot
- Seven Bridges vs LabVantage
- Seven Bridges vs Benchling
- Seven Bridges vs Sapio Sciences
- Seven Bridges vs Medidata Rave
- Seven Bridges vs Castor EDC
- Seven Bridges vs Suzy
- Seven Bridges vs Terra
- Seven Bridges vs LabWare
- Seven Bridges vs Aurelius
- Seven Bridges vs Chemaxon
- Seven Bridges vs Labguru
- Seven Bridges vs Schrodinger
- Seven Bridges vs TetraScience
- Seven Bridges vs Thermo SampleManager LIMS
- Seven Bridges vs Valispace
- Seven Bridges vs Wolfram Mathematica
- Seven Bridges vs DNAnexus
- Seven Bridges vs Dotmatics
- Seven Bridges vs Form Bio
- Seven Bridges vs Greenphire
- Seven Bridges vs OpenEye, Cadence Molecular Sciences
- Seven Bridges vs Attest
- Seven Bridges vs NVivo
- Seven Bridges vs Scispot